Redhill Biopharma Ltd (RDHL) FinancialsRDHLRedhill Biopharma Ltd

Redhill Biopharma Ltd (RDHL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial operations, accounting for 55.4% of total sales, equivalent to $7.10M. Another important revenue stream is Research and Development. Understanding this composition is critical for investors evaluating how RDHL navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Redhill Biopharma Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2765.38%, while the net margin is -2825.17%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RDHL converts its operational activities into shareholder value.

In the context of the broader market, RDHL competes directly with industry leaders such as SILO and MBIO. With a market capitalization of $4.02M, it holds a significant position in the sector. When comparing efficiency, RDHL's gross margin of 100.00% stands against SILO's -14.77% and MBIO's N/A. Such benchmarking helps identify whether Redhill Biopharma Ltd is trading at a premium or discount relative to its financial performance.

The gross margin for Q4 2025 is projected at 100%, but the net margin is heavily negative at -2825.17%, highlighting severe profitability challenges. The total equity is expected to improve to 4.268 million USD by Q4 2025, but the company has a current ratio below 1, indicating potential liquidity issues.